United States - English - NLM (National Library of Medicine)

29 luxury goods, inc. - avobenzone 3% w/w homosalate 10% w/w octisalate 5% w/w octocrylene 2% w/w oxybenzone 2.5% w/w, sunscreen - - helps prevent sunburn - if used as directed with other sun protection measures (see directions), decreases the risk of skin cancer and early skin aging caused by the sun

United States - English - NLM (National Library of Medicine)

glenmark generics inc., usa - norgestimate (unii: c291hfx4dy) (norgestimate - unii:c291hfx4dy), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - norgestimate 0.25 mg - norgestimate and ethinyl estradiol tablets usp are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. oral contraceptives are highly effective for pregnancy prevention. table ii lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, the iud, and the norplant system, depends upon the reliability with which they are used. correct and consistent use of methods can result in lower failure rates. method typical use§ perfect use¶ norgestimate and ethinyl estradiol tablets usp have not been studied for and are not indicated for use in emergency contraception. in clinical trials with norgestimate and ethinyl estradiol tablets, 1,651 subjects completed 24,272 cycles and the overall use-efficacy (typical user efficacy) pregnancy rate was approximately 1 pregnancy per 100 women-years. this rate includes patients who d

Canada - English - Health Canada

therapeutic foods co. - cobalt (cobalt gluconate) - liquid - 29.5mcg - cobalt (cobalt gluconate) 29.5mcg

United States - English - NLM (National Library of Medicine)

allergan, inc. - memantine hydrochloride (unii: jy0wd0ua60) (memantine - unii:w8o17sjf3t) - memantine hydrochloride 7 mg - namenda xr®  is indicated for the treatment of moderate to severe dementia of the alzheimer’s type. namenda xr is contraindicated in patients with known hypersensitivity to memantine hydrochloride or to any excipients used in the formulation. risk   summary   there are no adequate data on the developmental risk associated with the use of namenda xr in pregnant women.  adverse developmental effects (decreased body weight and skeletal ossification) were observed in the offspring of rats administered memantine during pregnancy at doses associated with minimal maternal toxicity. these doses are higher than those used in humans at the maximum recommended daily dose of namenda xr [see   data].    in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. the background risk of major birth defects and miscarriage for the indicated population is unknown. data animal   data oral administration of memantine 

United States - English - NLM (National Library of Medicine)

alvogen inc. - oxaliplatin (unii: 04zr38536j) (oxaliplatin - unii:04zr38536j) - oxaliplatin 5 mg in 1 ml - oxaliplatin injection, usp used in combination with infusional 5-fluorouracil/leucovorin, is indicated for: - adjuvant treatment of stage iii colon cancer in patients who have undergone complete resection of the primary tumor. - treatment of advanced colorectal cancer. oxaliplatin injection, usp should not be administered to patients with a history of known allergy to oxaliplatin injection, usp or other platinum compounds [see warnings and precautions (5.1)] . pregnancy category d based on direct interaction with dna, oxaliplatin injection, usp may cause fetal harm when administered to a pregnant woman. there are no adequate and well-controlled studies of oxaliplatin injection, usp in pregnant women. reproductive toxicity studies in rats demonstrated adverse effects on fertility and embryo-fetal development at maternal doses that were below the recommended human dose based on body surface area. if this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should

United States - English - NLM (National Library of Medicine)

glenmark pharmaceuticals inc., usa - norethindrone (unii: t18f433x4s) (norethindrone - unii:t18f433x4s), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - norethindrone 0.5 mg - alyacen 7/7/7 and alyacen 1/35 tabletsare indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. oral contraceptives are highly effective. table 1 lists the typical accidental pregnancy rates for users of combined oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, the iud, and the norplant® system depends upon the reliability with which they are used. correct and consistent use of methods can result in lower failure rates. chance# 85 85 spermicidesÞ 26 6 40 periodic abstinence 25 63   calendar 9   ovulation method 3   sympto-thermalß 2   post-ovulation 1 capà   parous women 40 26 42   nulliparous women 20 9 56 sponge   parous women 40 20 42   nulliparous women 20 9 56 diaphragmà 20 6 56 withdrawal 19 4 condomè   female (reality® ) 21 5 56   male 14 3 61 pill 5 71   progestin only 0.5   combined 0.1 iud   progesterone t 2 1.5 81   copper t380a 0.8 0.6 78   lng 20 0.1 0.1 81 depo-provera® 0.3 0.3 70 norplant® and norplant-2® 0.05 0.05 88 female sterilization 0.5 0.5 100 male sterilization 0.15 0.10 100 alyacen 7/7/7 and alyacen 1/35 have not been studied for and are not indicated for use in emergency contraception. oral contraceptives should not be used in women who currently have the following conditions:

United States - English - NLM (National Library of Medicine)

glenmark pharmaceuticals inc., usa - desogestrel (unii: 81k9v7m3a3) (desogestrel - unii:81k9v7m3a3), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - desogestrel 0.15 mg - oral contraceptives should not be used in women who currently have the following conditions:

United States - English - NLM (National Library of Medicine)

glenmark pharmaceuticals inc., usa - norethindrone (unii: t18f433x4s) (norethindrone - unii:t18f433x4s) - norethindrone 0.35 mg - progestin-only oral contraceptives are indicated for the prevention of pregnancy. if used perfectly, the first-year failure rate for progestin-only oral contraceptives is 0.3%. however, the typical failure rate is estimated to be closer to 9%, due to late or omitted pills. table 1 lists the pregnancy rates for users of all major methods of contraception.   % of women experiencing an unintended pregnancy within the first year of use % of women continuing use at one year method (1) typical use (2) perfect use (3) (4) no method4 85 85 spermicides 28 18 42 fertility awareness-based methods 24 47 standard days method6 5 twoday method6 4 ovulation method6 3 symptothermal method6 0.4 withdrawal 22 4 46 sponge 36 parous women 24 20 nulliparous women 12 9 condom7 female (fc) 21 5 41 male 18 2 43 diaphragm8 12 6 57 combined pill and progestin-only pill 9 0.3 67 norelgestromin and ethinyl estradiol patch 9 0.3 67 nuvaring 9 0.3 67 depo-provera 6 0.2 56 intrauterine contraceptives paragard (copper t) 0.8 0.6 78 mirena (lng) 0.2 0.2 80 implanon 0.05 0.05 84 female sterilization 0.5 0.5 100 male sterilization 0.15 0.10 100 notes: norethindrone tablets have not been studied for and are not indicated for use in emergency contraception. progestin-only oral contraceptives (pops) should not be used by women who currently have the following conditions:

United States - English - NLM (National Library of Medicine)

amneal pharmaceuticals of new york llc - colestipol hydrochloride (unii: x7d10k905g) (colestipol - unii:k50n755924) - colestipol hydrochloride 5 g - since no drug is innocuous, strict attention should be paid to the indications and contraindications, particularly when selecting drugs for chronic long-term use. colestipol hydrochloride for oral suspension is indicated as adjunctive therapy to diet for the reduction of elevated serum total and low-density lipoprotein (ldl) cholesterol in patients with primary hypercholesterolemia (elevated low density lipoproteins [ldl] cholesterol) who do not respond adequately to diet. generally, colestipol hydrochloride for oral suspension has no clinically significant effect on serum triglycerides, but with its use triglyceride levels may be raised in some patients. therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. treatment should begin and continue with dietary therapy (see ncep guidelines). a minimum of six months of intensive dietary therapy and counseling should be carried out prior to initiation of drug therapy. shorter periods may be considered in patients with severe elevations of ldl-c or with definite chd. according to the ncep guidelines, the goal of treatment is to lower ldl-c, and ldl-c is to be used to initiate and assess treatment response. only if ldl-c levels are not available, should the total-c be used to monitor therapy. the ncep treatment guidelines are shown below. ldl-cholesterol mg/dl (mmol/l) definite atherosclerotic disease* two or more other risk factors** initiation level goal no no ≥ 190 (≥ 4.9) < 160 (< 4.1) no yes ≥ 160 (≥ 4.1) < 130 (< 3.4) yes yes or no ≥ 130 (≥ 3.4) ≤ 100 (≤ 2.6) * coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). ** other risk factors for coronary heart disease (chd) include: age (males: ≥ 45 years; females: ≥ 55 years or premature menopause without estrogen replacement therapy); family history of premature chd; current cigarette smoking; hypertension; confirmed hdl-c < 35 mg/dl (0.91 mmol/l); and diabetes mellitus. subtract one risk factor if hdl-c is ≥ 60 mg/dl (1.6 mmol/l). colestipol hydrochloride for oral suspension is contraindicated in those individuals who have shown hypersensitivity to any of its components.

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - risedronate sodium monohydrate (unii: f67l43ut5c) (risedronic acid - unii:km2z91756z) - risedronate sodium 5 mg - risedronate sodium tablets are indicated for the treatment and prevention of osteoporosis in postmenopausal women. in postmenopausal women with osteoporosis, risedronate sodium tablets reduce the incidence of vertebral fractures and a composite endpoint of nonvertebral osteoporosis-related fractures [see clinical studies (14.1, 14.2) ]. risedronate sodium tablets are indicated for treatment to increase bone mass in men with osteoporosis. risedronate sodium tablets are indicated for the treatment and prevention of glucocorticoid-induced osteoporosis in men and women who are either initiating or continuing systemic glucocorticoid treatment (daily dosage of greater than or equal to 7.5 mg of prednisone or equivalent) for chronic diseases. patients treated with glucocorticoids should receive adequate amounts of calcium and vitamin d. risedronate sodium tablets are indicated for treatment of paget’s disease of bone in men and women. the optimal duration of use has not been determined. the safety and effectiveness